Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis
NCT04219358 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49
Last updated 2022-11-22
Summary
Actinic cheilitis is a potentially malignant lesion on the lower lip, which can progress to more serious illnesses such as cancer if not treated. Usually treatment of this condition is only based on clinical appearance, but there is no established cure treatment. Topical imiquimod is a medicine indicated for the treatment of skin diseases, but it has not yet been proven to treat actinic cheilitis. In this research, the investigator's aim is to evaluate the response to actinic cheilitis treatment with the current standard treatment compared to high and low concentration imiquimod topical formulations.
Conditions
- Actinic Cheilitis
Interventions
- DRUG
-
Vehicle Gel Base
Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks. Gel components: medium molecular weight chitosan, lactic acid 85% and water.
- DRUG
-
Imiquimod 5% gel
Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks. Gel components: medium molecular weight chitosan, lactic acid 85% and free form imiquimod 5%.
- DRUG
-
Imiquimod 0,05% gel
Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks. Gel components: medium molecular weight chitosan, lactic acid 85% and imiquimod 0.05% free form.
- DRUG
-
Imiquimod nanoencapsulated 0,05% gel
Apply 0.5ml of gel stored in a 1ml syringe over the lip 3 times a week (Mondays, Wednesdays and Fridays) at night for a period of 4 weeks. Gel components: medium molecular weight chitosan, lactic acid 85% and imiquomod in a nanoencapsulated suspension at concentration of 0,05%
- DRUG
-
Lip sunscreen 30 Sun Protector Factor (SPF)
Apply sunscreen on the lip 30 minutes every day before sun exposure. Protects against both UVA (ultraviolet A) and UVB (ultraviolet B rays).
- DRUG
-
Dexpanthenol
Apply dexpanthenol on the lip, two (2) times a day, once in the morning and once in the afternoon. Reduces transepidermic water loss and maintaining the natural smoothness and elasticity of the skin. It accelerates the cell renewal, rebuilds damaged tissues and promote the normal keratinisation of the skin and hair.
Sponsors & Collaborators
-
Federal University of Rio Grande do Sul
collaborator OTHER -
Hospital de Clinicas de Porto Alegre
lead OTHER
Principal Investigators
-
Fernanda Visioli, PhD · Federal University of Rio Grande do Sul
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-03-23
- Primary Completion
- 2020-06-24
- Completion
- 2021-08-24
Countries
- Brazil
Study Locations
More Related Trials
-
Topical Imiquimod for Bowen's Disease of the Head and Neck
NCT00384124 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
NCT00116649 ·Status: COMPLETED ·Phase: PHASE4
-
Photoaging Treatment With Imiquimod
NCT01935310 ·Status: COMPLETED ·Phase: NA
-
A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the Hand
NCT00544297 ·Status: COMPLETED ·Phase: PHASE2
-
Imiquimod and Actinic Keratoses: an Observational Study
NCT01151956 ·Status: COMPLETED
-
A Study to Evaluate the Effectiveness and Safety of Multiple Applications of Imiquimod 5% Cream for the Treatment of Actinic Keratoses in Organ Transplant Recipients
NCT00189267 ·Status: COMPLETED ·Phase: PHASE2
-
Trichloroacetic Acid as a Topical Treatment for Actinic Cheilitis
NCT04744103 ·Status: WITHDRAWN ·Phase: PHASE4
-
Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses
NCT01229319 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)
NCT00605176 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Topical Imiquimod on Lentigo Maligna
NCT01161888 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
NCT00427050 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2
NCT00659893 ·Status: COMPLETED ·Phase: PHASE1
-
Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna
NCT01088737 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)
NCT00603798 ·Status: COMPLETED ·Phase: PHASE3
-
Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis
NCT02278861 ·Status: COMPLETED ·Phase: PHASE2
-
Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
NCT04842422 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses
NCT00107965 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Actinic Cheilitis
NCT02198469 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment
NCT03452566 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
NCT02281682 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
NCT00375739 ·Status: COMPLETED ·Phase: PHASE2
-
The Real Life Topical Field Treatment of Actinic Keratosis Study
NCT02362152 ·Status: COMPLETED
-
Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis
NCT02242747 ·Status: COMPLETED ·Phase: NA
-
Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel
NCT00239135 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
NCT00786994 ·Status: COMPLETED ·Phase: PHASE2